Cat. No.: HY-D0885

Phosphocreatine

(Synonyms: Creatine phosphate; Creatinephosphoric acid)

3 Cited Publications

Customer Review

Based on 3 publication(s) in Google Scholar

Phosphocreatine (creatine phosphate) is an organic compound found in vertebrate skeletal muscles. Phosphocreatine enhances antioxidant activity, and activates the TAK1 pathway to protect the heart. Phosphocreatine normalizing mitochondrial function and reducing oxidative stress via Akt mediated Nrf2/HO-1 pathway. Phosphocreatine provides renal protection by suppressing Apoptosis and ROS (Reactive Oxygen Species) generation through ERK mediated mediated Nrf-2/HO-1 pathway..

For research use only. We do not sell to patients.

Purity: 99.60%
CAS No.: 67-07-2
Formula: C₄H₁₀N₃O₅P
Molecular Weight:211.11

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Phosphocreatine Chemical Structure

CAS No.: 67-07-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

Human Endogenous Metabolite

All Endogenous Metabolite Isoforms :

All MAP3K Isoforms :

All Akt Isoforms :

All ERK Isoforms :

In Vitro

Phosphocreatine (0-1 mM, 24 h) reveals the effect of anti-oxidant, anti-apoptosis and anti-necroptosis to protect agaist DOX (Doxorubicin) (HY-15142A)-induced cardiomyocytes injury in H9c2 cells by targeting TAK1^[2].
Phosphocreatine (0-1 mM, 24 h) alleviates oxidative stress by increasing antioxidant activity, subsequently recovers expression level of TAK1 to baseline and reduces apoptosis and necroptosis in DOX-induced myocardial injury^[2].
Phosphocreatine (5-20 mM, 24 h) attenuates cell injury and inhibits apoptosis induced by MGO (Methylglyoxal) (HY-106634) in PC12 cell^[3].
Phosphocreatine (5-20 mM, 24 h) prevents loss of mitochondrial membrane permeability of MGO (Methylglyoxal) injured PC-12 cells^[3].
Phosphocreatine (5-20 mM, 2 h) exhibits the neuroprotective effects in PC-12 cells relying on normalizing mitochondrial function and reducing oxidative stress via Akt mediated Nrf2/HO-1 pathway^[3].
Phosphocreatine (5-40 mM, 24 h) at different concentrations might contribute to protection of the NRK-52E cells against MGO-induced kidney injury^[4].
Phosphocreatine (10-40 mM, 4 h) suppresses kidney oxidative stress metabolites^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]^[4]

Cell Line:

PC-12, NRK-52E cells
Concentration:

0, 5, 10, 20, 40 mM
Incubation Time:

24 h
Result:

Was not toxic to PC-12 cells under the treatment conditions.
Significantly increased PC-12 cell viability at the concentrations of 5, 10 and 20 mM compared with MGO (Methylglyoxal) (HY-106634) groups.
Contributed to protection of the NRK-52E cells against MGO-induced kidney injury.

Apoptosis Analysis^[3]^[4]

Cell Line:

PC-12, NRK-52E cells
Concentration:

5, 10, 20, 40 mM
Incubation Time:

2 h
Result:

Significantly suppressed the enhanced early apoptosis in PC-12 cells in a dose-dependent manner.
Increased the expression of Bcl-2, procaspase-3 and procaspase-9 in NRK-52E cells.
Decreased the expression of Bax and cleaved caspase-3 in NRK-52E cells..
Suppressed karyorrhexis and karyopyknosis in NRK-52E cells..
Decreased the apoptotic rate compared with MGO-treated cells in NRK-52E cells..
Prevented the losing of MMP (mitochondrial membrane potential) in NRK-52E cells.

Western Blot Analysis^[3]^[4]

Cell Line:

PC-12, NRK-52E cells
Concentration:

20, 40 mM
Incubation Time:

24 h
Result:

Increased the expression levels of Akt, Nrf2 (nuclear factor (erythroid-derived-2)-like 2 (Nrf2)) and HO-1 (Hemeoxygenase-1) in PC12 cells.
Increased the expression of nuclear Nrf2 levels, and decreased Nrf2 level in PC12 cells cytoplasm.
Increased the expression of p-Akt, HO-1 and Nrf2 with compared with pre-treatment for 2 h with LY294002 (a PI3K inhibitor) in PC12 cells.
Significantly increased Bcl-2 and procaspase-9 levels and decreased Bax, cleaved caspase-9 and cleaved caspase-3 C level in NRK-52E cells.
Decreased the expression of p-ERK and increased the Nrf2 and HO-1 expressions in NRK-52E cells.

In Vivo

Phosphocreatine (200 mg/kg, i.p., once every other day, 7 weeks) not only alleviates oxidative stress and myocardial apoptosis, but also rescues myocardial necroptosis in DOX-induced cardiotoxicity of rat^[2].
Phosphocreatine (20-40 mg/kg, i.v., daily, 6 weeks) has a protective effect on the kidney tissues against diabetic nephropathy in SD (Sprague Dawley) rats^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Sprague Dawley (SD) rats, i.p., normal saline, 3 times; i.p., DOX 2 mg/kg, 7 times; i.p., normal saline, 3 times ^[2].
Dosage:

200 mg/kg
Administration:

i.p., once every other day, 7 weeks
Result:

Improved the heart function abnormality.
Lowered myocardial apoptosis.
Recovered the expression of Nrf2, SOD, FoxO3a and diminished C-Casp3, Bax/Bcl2 in the myocardial tissue of rats.
Markedly improved myocardial necroptosis, as indicated by decreasing expression of RIP3 and CaMKII.
Increased expression level of TAK1.

Animal Model:

Male Sprague Dawley (SD) rats, i.p., 70 mg/kg (STZ(Streptozotocin) (HY-13753)), daily, 6 weeks ^[4].
Dosage:

20, 40 mg/kg
Administration:

i.p., daily, 6 weeks
Result:

Reduced hyperglycemia compared with STZ (Streptozotocin) (HY-13753) -treated rats.
Increased the weight of rats gradually compared with STZ (Streptozotocin) (HY-13753) group.
Decreased kidney weight index (kidney weight/body weight).
Decreased MDA level and increased of GSH and SOD levels compared with STZ group.
Decreased the apoptotic rate compared with MGO-treated groups.

Chemical Information

CAS No. 67-07-2
Appearance Solid
Molecular Weight 211.11
Formula C₄H₁₀N₃O₅P
Color White to off-white
SMILES

O=C(O)CN(C(NP(O)(O)=O)=N)C
Synonyms

Creatine phosphate; Creatinephosphoric acid
Structure Classification
- Ketones, Aldehydes, Acids
Initial Source
- Animals
- Endogenous metabolite
skeletal muscles of vertebrates
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (3)

All

Sort by:

Journal Impact Factor

Autophagy

ESCRT III-mediated lysosomal repair improve renal tubular cell injury in cisplatin-induced AKI. [Abstract]

2025 Mar 28. PMID: 40152606
Neuron

2025 Dec 17.
Toxicol Appl Pharmacol

Cytochalasin Q exerts anti-melanoma effect by inhibiting creatine kinase B. [Abstract]

2022 Apr 15:441:115971. PMID: 35276125

Solvent & Solubility

In Vitro:

H₂O : 175 mg/mL (828.95 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.7369 mL

23.6843 mL

47.3687 mL

5 mM

0.9474 mL

4.7369 mL

9.4737 mL

10 mM

0.4737 mL

2.3684 mL

4.7369 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Feldman EB, et al. Creatine: a dietary supplement and ergogenic aid. Nutr Rev. 1999 Feb;57(2):45-50. [Content Brief]

[2]. Wang C, et al. Phosphocreatine attenuates doxorubicin-induced cardiotoxicity by inhibiting oxidative stress and activating TAK1 to promote myocardial survival in vivo and in vitro. Toxicology. 2021 Aug;460:152881. [Content Brief]

[3]. Li H, et al. Neuroprotective effect of phosphocreatine on oxidative stress and mitochondrial dysfunction induced apoptosis in vitro and in vivo: Involvement of dual PI3K/Akt and Nrf2/HO-1 pathways. Free Radic Biol Med. 2018 May 20;120:228-238. [Content Brief]

[4]. Shopit A, et al. Protection of diabetes-induced kidney injury by phosphocreatine via the regulation of ERK/Nrf2/HO-1 signaling pathway. Life Sci. 2020 Feb 1;242:117248. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	4.7369 mL	23.6843 mL	47.3687 mL	118.4217 mL
	5 mM	0.9474 mL	4.7369 mL	9.4737 mL	23.6843 mL
	10 mM	0.4737 mL	2.3684 mL	4.7369 mL	11.8422 mL
	15 mM	0.3158 mL	1.5790 mL	3.1579 mL	7.8948 mL
	20 mM	0.2368 mL	1.1842 mL	2.3684 mL	5.9211 mL
	25 mM	0.1895 mL	0.9474 mL	1.8947 mL	4.7369 mL
	30 mM	0.1579 mL	0.7895 mL	1.5790 mL	3.9474 mL
	40 mM	0.1184 mL	0.5921 mL	1.1842 mL	2.9605 mL
	50 mM	0.0947 mL	0.4737 mL	0.9474 mL	2.3684 mL
	60 mM	0.0789 mL	0.3947 mL	0.7895 mL	1.9737 mL
	80 mM	0.0592 mL	0.2961 mL	0.5921 mL	1.4803 mL
	100 mM	0.0474 mL	0.2368 mL	0.4737 mL	1.1842 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Phosphocreatine

3 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Phosphocreatine

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Human Endogenous Metabolite Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Glucose Metabolism Compound Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Human Metabolite Library

Osteogenesis Compound Library

Cuproptosis Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Animal-Sourced Natural Product Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Endogenous Metabolite Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Amino Acid Metabolite Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Phosphocreatine

All Endogenous Metabolite Isoforms

All MAP3K Isoforms

All Akt Isoforms

All ERK Isoforms

Biological Activity

Chemical Information

Publications (3)

Solvent & Solubility

Purity & Documentation